Algo v0.31
Substrate
science

Acting Director of FDA Drug Center Tracy Beth Høeg Leaves Agency

Tracy Beth Høeg, acting director of the Food and Drug Administration’s Center for Drug Evaluation and Research, is departing the agency. The departure comes days after Commissioner Marty Makary submitted his resignation. Michael Davis, the center’s current deputy director, will assume the role of acting director.

Stat
1 source·May 15, 9:52 PM(13 days ago)·1m read
Acting Director of FDA Drug Center Tracy Beth Høeg Leaves AgencyStat
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources familiar with the matter. The departure comes days after Commissioner Marty Makary handed in his resignation. Michael Davis, currently the center’s deputy director, will take over as acting director.

The FDA and Høeg did not immediately respond to requests for comment. Reuters and Bloomberg first reported the news.

The changes leave the agency facing a leadership vacuum at a time when it oversees regulation of pharmaceuticals and public health decisions. Høeg had been serving in the acting director role for the drug center. Her exit follows the commissioner’s resignation by only a few days, according to the sources.

The FDA did not provide further details on the reasons for the departures or on any timeline for appointing permanent leadership.

Key Facts

Tracy Beth Høeg
leaving as acting director of FDA drug center
Marty Makary
resigned as FDA commissioner days earlier
Michael Davis
deputy director becomes new acting director
FDA response
did not immediately comment on departures
fdahealth-policyleadership-changespharmaceutical-regulation

Story Timeline

3 events
  1. May 15, 2026

    Tracy Beth Høeg departs as acting director of FDA drug center.

    1 source@statnews
  2. Early May 2026

    Commissioner Marty Makary submitted his resignation.

    1 source@statnews
  3. May 15, 2026

    Michael Davis named acting director of the drug center.

    1 source@statnews

Potential Impact

  1. 01

    The FDA drug center will operate under new acting leadership following two high-level departures.

  2. 02

    Ongoing pharmaceutical reviews and approvals may face temporary delays during the leadership transition.

  3. 03

    The agency did not disclose plans or timelines for filling the positions on a permanent basis.

Transparency Panel

Sources cross-referenced1
Confidence score75%
Synthesized bySubstrate AI
Word count146 words
PublishedMay 15, 2026, 9:52 PM
Bias signals removed1 across 1 outlet
Signal Breakdown
Framing 1
Original Sources
StatThe acting director of the FDA’s drug center, Tracy Beth Høeg, is leaving the agency.

Related Stories

WHO Director Visits Congo as Ebola Outbreak SpreadsNpr
science4 hrs ago

WHO Director Visits Congo as Ebola Outbreak Spreads

The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.

Npr
France 24
2 sources
FDA Panel Recommends XFG Variant for Fall Covid Shotsmedpagetoday.com
science2 hrs agoDeveloping

FDA Panel Recommends XFG Variant for Fall Covid Shots

Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.

Stat
1 source
Benzinga Publishes Article on Biotech Stocks During Pandemic Recoveryfinance.yahoo.com
science6 hrs agoDeveloping

Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery

Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…

Benzinga
1 source